Therapies targeting triple-negative breast cancer: a perspective on anti-FGFR
Triple-negative breast cancer (TNBC) is one of the subtypes with the worst prognosis due to tumour heterogeneity and lack of appropriate treatment. This condition is a consequence of the distinctive tumour microenvironment (TME). The TME is associated with factors such as the promotion of proliferat...
Saved in:
| Main Authors: | Jinhao Chen, Qianru Wang, Hongyan Wu, Xiaofei Huang, Chunyu Cao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1415820/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Erdafitinib inhibits the tumorigenicity of MDA-MB-231 triple-negative breast cancer cells by inducing TRIM25/ubiquitin-dependent degradation of FGFR4
by: Qing Luo, et al.
Published: (2025-07-01) -
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma
by: Arianna Giacomini, et al.
Published: (2024-11-01) -
FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies
by: Maxim Noeraparast, et al.
Published: (2024-10-01) -
FGFR2 identified as a NETs-associated biomarker and therapeutic target in diabetic foot ulcers
by: Linrui Dai, et al.
Published: (2025-08-01) -
Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma
by: Katherine J. Crawford, et al.
Published: (2025-07-01)